Free tool
Oncology stocks
We cover 48 companies grouped under the Oncology theme. The median market value in the group is $81.10M. Across the group, the median move over the past trading day is +1.58%. 51% of the 47 with a 200-day average trade above it. Price change over the past year runs from −77.0% to +282.5% across the middle 80 percent of the group, with a median of −5.9%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
48 of 319 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| 6MK.DE | Merck & Co., Inc. | 129.28 EUR | +11.62% | +44.70% | +83.96% | Oct 29, 2026 |
| MRK | Merck & Co., Inc. | $156.45 | +19.65% | +48.06% | +88.17% | Oct 29, 2026 |
| AZN.L | AstraZeneca PLC | 12,110.00 GBP | −6.41% | −10.89% | +1.98% | Oct 30, 2026 |
| AZN | AstraZeneca PLC | $169.66 | +0.01% | −6.39% | +7.60% | Oct 30, 2026 |
| 4528.T | Ono Pharmaceutical Co., Ltd. | 2,511.00 JPY | +3.89% | +16.57% | +62.22% | Oct 29, 2026 |
| LNTH | Lantheus Holdings, Inc. | $100.87 | −6.63% | +49.95% | +79.61% | Nov 5, 2026 |
| COGT | Cogent Biosciences, Inc. | $36.80 | −9.00% | +5.93% | +212.13% | Nov 3, 2026 |
| ERAS | Erasca, Inc. | $17.76 | −5.88% | +394.71% | +1016.98% | Nov 11, 2026 |
| RLAY | Relay Therapeutics, Inc. | $20.57 | +10.35% | +151.47% | +486.04% | Nov 5, 2026 |
| CELC | Celcuity Inc. | $92.27 | +12.16% | −8.23% | +87.35% | Nov 11, 2026 |
| TNGX | Tango Therapeutics, Inc. | $24.51 | −8.27% | +174.47% | +264.73% | Nov 4, 2026 |
| RCUS | Arcus Biosciences, Inc. | $31.57 | +13.40% | +35.55% | +211.03% | Oct 27, 2026 |
| IMNM | Immunome, Inc. | $29.39 | +30.14% | +41.14% | +196.22% | Nov 5, 2026 |
| ZLAB | Zai Lab Limited | $26.17 | +40.40% | +51.01% | −23.10% | Nov 5, 2026 |
| SLS | SELLAS Life Sciences Group, Inc. | $14.09 | +29.98% | +223.91% | +637.70% | Nov 11, 2026 |
| NRIX | Nurix Therapeutics, Inc. | $26.95 | +15.02% | +49.22% | +178.70% | Oct 8, 2026 |
| NUVB | Nuvation Bio Inc. | $7.10 | +6.61% | −17.25% | +146.53% | Nov 2, 2026 |
| URGN | UroGen Pharma Ltd. | $46.36 | +11.82% | +104.14% | +150.59% | Nov 5, 2026 |
| XNCR | Xencor, Inc. Common Stock | $29.30 | +47.53% | +96.38% | +265.79% | Nov 4, 2026 |
| NANO.PA | Nanobiotix S.A. | 34.14 EUR | +3.96% | +79.68% | +341.09% | Sep 29, 2026 |
| NBTX | Nanobiotix S.A. | $41.51 | +3.31% | +87.57% | +321.42% | Sep 29, 2026 |
| NVCR | NovoCure Limited | $17.62 | +3.46% | +34.30% | +50.60% | Oct 29, 2026 |
| OSE.PA | OSE Immunotherapeutics SA | 3.19 EUR | +0.69% | −39.85% | −47.82% | Sep 28, 2026 |
| 0J4V.L | Heron Therapeutics, Inc. | $0.32 | +1.38% | −74.92% | −76.73% | Nov 3, 2026 |
| CRDF | Cardiff Oncology, Inc. | $1.02 | +21.43% | −61.65% | −53.85% | Nov 12, 2026 |
| OSTX | OS Therapies Incorporated | $1.65 | +7.84% | +23.13% | −24.66% | Nov 16, 2026 |
| PLRX | Pliant Therapeutics, Inc. | $1.14 | +5.56% | −8.80% | −23.49% | Nov 5, 2026 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.31 | +10.59% | +6.10% | −8.10% | Nov 16, 2026 |
| HRTX | Heron Therapeutics, Inc. | $0.32 | −29.76% | −74.36% | −76.59% | Nov 3, 2026 |
| IMMP | Immutep Limited | $0.38 | +0.50% | −87.05% | −77.54% | Sep 2, 2026 |
| 0RAD.L | OSE Immunotherapeutics SA | 3.16 EUR | −2.11% | −40.40% | −48.92% | Sep 28, 2026 |
| HOWL | Werewolf Therapeutics, Inc. | $0.89 | +96.47% | +37.98% | −35.04% | Oct 30, 2026 |
| KPTI | Karyopharm Therapeutics Inc. Common Stock | $1.92 | −72.92% | −73.30% | −69.57% | Nov 3, 2026 |
| KYNB | Kyntra Bio, Inc. | $8.10 | +14.89% | −11.57% | −23.80% | Nov 9, 2026 |
| 4582.T | SymBio Pharmaceuticals Limited | 63.00 JPY | −7.35% | −30.00% | −58.28% | Oct 29, 2026 |
| BYSI | BeyondSpring Inc. | $0.72 | −38.44% | −55.27% | −60.43% | Nov 12, 2026 |
| MDNA.TO | Medicenna Therapeutics Corp. | 0.47 CAD | +36.23% | −53.00% | −58.77% | Nov 12, 2026 |
| LTRN | Lantern Pharma Inc. | $2.18 | −21.86% | −29.90% | −52.30% | Nov 11, 2026 |
| CLRB | Cellectar Biosciences, Inc. | $2.54 | +4.96% | −26.80% | −45.96% | Nov 12, 2026 |
| BFRI | Biofrontera Inc. | $1.51 | +43.81% | +108.28% | +63.77% | Nov 11, 2026 |
| TPST | Tempest Therapeutics, Inc. | $1.11 | +18.72% | −62.37% | −89.50% | Nov 5, 2026 |
| LSTA | Lisata Therapeutics, Inc. | $1.74 | +20.83% | −11.22% | −31.23% | Nov 5, 2026 |
| BLRX | BioLineRx Ltd. | $2.85 | +1.06% | +1.79% | −25.97% | Aug 31, 2026 |
| PDSB | PDS Biotechnology Corporation | $0.22 | −68.04% | −73.41% | −82.96% | Nov 12, 2026 |
| LNAI | Lunai Bioworks Inc. | $2.20 | −1.35% | −71.71% | −87.99% | Sep 28, 2026 |
| 0GP7.L | Medivir AB (publ) | 2.08 SEK | +9.14% | +355.54% | +3.85% | Nov 5, 2026 |
| BCAB | BioAtla, Inc. | $3.26 | −4.12% | −87.79% | −81.69% | Nov 12, 2026 |
| CRIS | Curis, Inc. | $1.59 | −66.10% | +62.24% | −3.64% | Nov 5, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.